Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GLPG3067 +/- GLPG2222 and GLPG2737 in Healthy Women
NCT03128606Phase 1Completed
- Sponsor
- Galapagos NV
- Start
- Mar 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of navocaftor in cystic fibrosis (CF), sponsored by Galapagos NV. Primary endpoint: Change versus placebo in the proportion of subjects with adverse events. Started Mar 2017; status: completed.
02
Drugs
navocaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03128606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03128606.